COMP <GO>
BMRN vs SMMT // EV/EBITDA & P/E VALUATION
BioMarin Pharmaceutical Inc. (NASDAQ) VS. Summit Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BMRN 8
— SMMT 3
■ METRIC PARITY
LAST: $57.44 (-1.83%) • MKT CAP: $11.33B
valuation
21.0x
LAST: $14.80 (-7.67%) • MKT CAP: $12.82B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. SMMT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | SMMT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | -35.00% | +41.00 | BMRN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.51% | -2.50% | +9.01 | BMRN | /fcf-yield <GO> |
| Operating Margin | 12.70% | -36.30% | +49.00 | BMRN | /operating-margins <GO> |
| Net Profit Margin | 10.80% | -29.80% | +40.60 | BMRN | /net-margins <GO> |
| Revenue Growth (YoY) | 12.90% | 11.00% | +1.90 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.57 | 26.00 | -20.43 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.4 | 50.5 | +3.90 | BMRN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.97 | -0.02 | SMMT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 34.0x | -7.20 | BMRN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.33B | $12.82B | -$1.49B | SMMT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | SMMT REV | BMRN GROSS % | SMMT GROSS % | BMRN FCF | SMMT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $3.57B | 77.7% | — | $725.0M | -$323.6M |
| FY 2024 | $2.85B | $632.8M | 79.7% | — | $487.4M | -$142.2M |
| FY 2023 | $2.42B | $1.71B | — | — | $50.4M | -$76.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
SMMT // BETA 0.97